Skip to main content

Simeon I. Taylor, MD, PhD

Academic Title:

Professor

Primary Appointment:

Medicine

Location:

MSTF, 357B

Phone (Primary):

410-706-6439

Education and Training

  • Harvard College, BA, 1969
  • Harvard University, PhD, 1974
  • Harvard Medical School, MD, 1976
  • Residency, Internal Medicine, Massachusetts General Hospital, 1976-78
  • Fellowships, Endocrinology & Metabolism, Massachusetts General Hospital, 1978-79; National Institutes of Health Inter-Institute Training Program in Endocrinology, 1979-81

Biosketch

Dr. Simeon Taylor received a B.A. (Chemistry) from Harvard College in 1969, followed by Ph.D. and M.D. degrees from Harvard Medical School in 1974 and 1976, respectively. He completed clinical training in the specialty of Internal Medicine and sub-specialty of Endocrinology & Metabolism at Massachusetts General Hospital (1976-1979) and National Institutes of Health (1979-1981). He worked in the Intramural Research Program of NIDDK (1979-2000), where he occupied positions of increasing responsibility, including Chief of the Diabetes Branch (1989-2000). His work at NIDDK was recognized by the Outstanding Service Award, Unites States Public Health Service (1990) and the Outstanding Scientific Achievement Award of the American Diabetes Association (1992). In addition, he served as Director of the NIH Inter-Institute Clinical Training Program in Endocrinology & Metabolism (1995-1998).

He moved to the pharmaceutical industry in 2000: first at Eli Lilly (2000-2002) where he was a Lilly Research Fellow in Endocrine Research and later at Bristol-Myers Squibb where he served as Vice President Cardiovascular & Metabolic Disease Research (2002-2010) and Vice President Research & Scientific Affairs (2010-2013). During his time at Bristol-Myers Squibb, he made substantial contributions to R&D leading to four approved drugs: saxagliptin, dapagliflozin, apixaban, and metreleptin.

He joined the faculty at the University of Maryland School of Medicine in 2013, first as an Adjunct Professor of Medicine (2013-2015) and currently as a Professor of Medicine. In addition, he serves as Director of the Mid-Atlantic Nutrition Obesity Research Center.

Research/Clinical Keywords

Diabetes, endocrinology, metabolism, insulin action, insulin resistance, pharmacology, pharmacogenetics, SGLT2 inhibitors, metreleptin

Highlighted Publications

  1. Kadowaki T, Bevins CL, Cama A, Ojamaa K, Marcus-Samuels B, Kadowaki H, Beitz L, McKeon C, Taylor SI (1988) Two mutant alleles of the insulin receptor gene in a patient with extreme insulin resistance. Science, 240: 787-790
  2. Taylor SI (1992) 1992 Lilly Lecture. Molecular mechanisms of insulin resistance: lessons from patients with mutations in the insulin receptor gene. Diabetes, 41: 1473-1490
  3. Arioglu-Oral E, Simha V, Ruiz E, Sebring N, Andewelt A, Premkumar A, Snell P, Wagner A, DePaoli A, Reitman ML, Taylor SI, Gorden P, Garg A (2002) Efficacy and safety of leptin replacement in treatment of lipodystrophy. N Engl J Med, 346: 570-578
  4. Taylor SI, Blau JE, Rother KI (2015) Possible adverse effects of SGLT2-inhibitors on bone. Lancet Diabetes & Endocrinology 3: 8-10
  5. Taylor, S.I., Blau, J.E., Rother, K.I.: SGLT2 inhibitors may predispose to ketoacidosis. J. Clin. Endocrinol. Metab., 100: 2849-2852, 2016

Additional Publication Citations

  1. Taylor SI, Grunberger G, Marcus-Samuels B, Underhill LH, Dons RF, Ryan J, Roddam RF, Rupe CE, Gorden P (1982) Hypoglycemia associated with antibodies to the insulin receptor. N Engl J Med, 307: 1422-1426. PMID: 7133096.
  2. Rees-Jones RW, Taylor SI (1985) An endogenous substrate for the insulin receptor-associated tyrosine kinase. J Biol Chem 260: 4461-4467. PMID: 3884611
  3. Perrotti N, Accili D, Marcus-Samuels B, Rees-Jones RW., Taylor SI (1987) Insulin stimulates phosphorylation of a 120-kDa glycoprotein substrate (pp120) for the receptor-associated protein kinase in intact H-35 hepatoma cells. Proc Natl Acad Sci USA 84: 3137-3140. PMID: 3033636
  4. Gherzi R, Russell DS, Taylor SI, Rosen OM (1987) Reevaluation of the evidence that an antibody to the insulin receptor is insulinmimetic without activating the protein tyrosine kinase activity of the receptor. J Biol Chem 262: 16900-16905. PMID: 3680277
  5. Margolis RN, Taylor SI, Seminara D, Hubbard AL (1988) Identification of pp120, an endogenous substrate for the hepatocyte insulin receptor tyrosine kinase, as an integral membrane glycoprotein of the bile canalicular domain. Proc Natl Acad Sci USA 85: 7256-7259. PMID: 2845403.
  6. Kadowaki T, Bevins CL, Cama A, Ojamaa K, Marcus-Samuels B, Kadowaki H, Beitz L, McKeon C, Taylor SI (1988) Two mutant alleles of the insulin receptor gene in a patient with extreme insulin resistance. Science, 240: 787-790. PMID: 2834824.
  7. Accili D, Frapier C, Mosthaf L, McKeon C, Elbein S, Permutt MA, Ramos E, Lander E, Ullrich A, Taylor SI (1989) A mutation in the insulin receptor gene that impairs transport of the receptor to the plasma membrane and causes insulin resistant diabetes. EMBO J, 8:2509-2517. PMID: 3573522.
  8. Kadowaki T, Kadowaki H, Taylor SI (1990) A nonsense mutation causing decreased levels of insulin receptor mRNA: Detection by a simplified technique for direct sequencing of genomic DNA amplified by polymerase chain reaction, Proc Natl Acad Sci USA, 87:658-662. PMID: 2300553.
  9. Hurley, DM Accili, D, Stratakis CA, Karl M, Vamvakopoulos N, Rorer E, Constantine K, Taylor SI, Chrousos, GP (1991) Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance. J Clin Invest 87: 680-686. PMID: 1704018
  10. Taylor SI (1992) 1992 Lilly Lecture. Molecular mechanisms of insulin resistance: lessons from patients with mutations in the insulin receptor gene. Diabetes, 41: 1473-1490. PMID: 1327927.
  11. Wertheimer E, Lu SP, Backeljauw PF, Davenport ML, Taylor SI (1993) Homozygous deletion of the human insulin receptor gene. Nature Genetics, 5:71-73. PMID: 7693131.
  12. Najjar SM, Accili, D, Philippe N, Jernberg J, Margolis R, Taylor SI (1993) pp120/ecto-ATPase, an endogenous substrate of the insulin receptor tyrosine kinase, is expressed as two variably spliced isoforms. J Biol Chem 268: 1201-1206. PMID: 8380406
  13. Quon MJ, Chen H, Ing BL, Liu ML, Zarnowski MJ, Yonezawa K, Kasuga M, Cushman SW, Taylor SI (1995) Roles of 1-phosphatidylinositol 3-kinase and ras in regulating translocation of GLUT4 in transfected rat adipose cells. Mol Cell Biol 15: 5403-5411. PMID: 7565691.
  14. Accili D, Drago J, Lee EJ, Johnson MD, Cool MH, Salvatore P, Asico LD, Jose PA, Taylor SI, Westphal H (1996) Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nat Genet 12: 106-109, 1996. PMID: 8528241
  15. Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Cochran C, Herion D, Kleiner D, Reynolds J, Premkumar A, Calis K, Gottlieb N, Lieberman J, Skarulis M, Sumner AE, Reitman ML, Taylor SI (2000) Efficacy of troglitazone in treatment of lipodystrophy syndromes: weighing the risks and benefits. Ann Intern Med, 133: 263-274. PMID: 10929166.
  16. Arioglu-Oral E, Simha V, Ruiz E, Sebring N, Andewelt A, Premkumar A, Snell P, Wagner A, DePaoli A, Reitman ML, Taylor SI, Gorden P, Garg A (2002) Efficacy and safety of leptin replacement in treatment of lipodystrophy. N Engl J Med, 346: 570-578. PMID: 11856796.
  17. Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, Cline GW, DePaoli AM, Taylor SI, Gorden P, Shulman GI (2002) Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest, 109: 1345-1350. PMID: 12021250.
  18. Agarwal AK, Arioglu E, de Almeida S, Akkoc N, Taylor SI, Bowcock AM, Barnes RI, Garg A (2002) AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nature Genetics, 31: 21-23. PMID: 11967537.
  19. Tozzo E, Ponticiello R, Swartz J, Farrelly D, Zebo R, Welzel G, Egan D, Kunselman L, Peters A, Gu L, French M, Chen S, Devasthale P, Janovitz E, Staal A, Harrity T, Belder R, Cheng PT, Whaley J, Taylor S, Hariharan N (2007) The dual peroxisome proliferator-activated receptor alpha/gamma activator muraglitazar prevents the natural progression of diabetes in db/db mice. J Pharmacol Exp Ther 321: 107-115. PMID: 17259449.
  20. Taylor SI, Blau JE, Rother KI (2015) Possible adverse effects of SGLT2-inhibitors on bone. Lancet Diabetes & Endocrinology 3: 8-10. PMID: 25523498.
  21. Taylor, S.I., Blau, J.E., Rother, K.I.: SGLT2 inhibitors may predispose to ketoacidosis. J. Clin. Endocrinol. Metab., 100: 2849-2852, 2016

Clinical Specialty Details

Diabetes, Endocrinology, and Metabolism

Awards and Affiliations

1968                Phi Beta Kappa, “Junior Eight” (Harvard College)

1969                Sophia Freund Award for best academic record at Harvard and Radcliffe Colleges

1971-1976       Scholar, Insurance Medical Scientist Fund

1974-1975       Fellow, Foundation for Research in Hereditary Disease

1986                Young Investigator Award, American Federation for Clinical Research (Eastern Section)

1990                Outstanding Service Award, Unites States Public Health Service

1992                American Diabetes Association: Outstanding Scientific Achievement Award

                        (“Eli Lilly Award”)

Grants and Contracts

R21DK105401 (NIH/NIDDK)                           4/2015-3/31/17                       $230,250

Pharmacogenetics of SGLT2 inhibitors: Pilot & Feasibility Project

This study will evaluate variable responses to SGLT2 inhibitors by enrolling subjects with loss of function mutations in SGLT-gene family members (SLC5A4 and SLC5A9) as well as SLC2A9 in the Old Order Amish.

Role: Principal Investigator

 _________________________________________________________________________________________

P30DK072488 (NIH/NIDDK)                           07/01/15 – 6/30/20                      $819,118                            

Mid-Atlantic Nutrition Obesity Research Center

The NORC of Maryland will focus on physiology and pathophysiology related to nutrition and obesity – including the impact upon the risk for diseases such as type 2 diabetes, nonalcoholic fatty liver disease, cardiovascular disease (CVD), sleep disordered breathing, and osteoporosis. 

Role: Program Director

 _________________________________________________________________________________________

T32DK098107                                                 07/01/15 – 06/30/20                      $200,670

Diabetes and its Metabolic Complications

This training grant will provide stipends to support two pre-doctoral fellowships and two post-doctoral fellowships for research trainees working in laboratories at the University of Maryland School of Medicine under the supervision of experienced mentors working in the field of diabetes research.  The training grant will provide stipend support for a maximum of three years.

Role: Program Director

_________________________________________________________________________________________

1-16-ICTS-112 (Amer. Diabetes Assoc.)        01/15/16 – 12/31/18                               $199,972            

Pharmacogenomics of GLP1 Receptor Agonists: Pilot Study Investigating Nonsynonymous Variants in Two Candidate Genes (GIPR and GCGR).

This study evaluate variable responses to GLP1 receptor agonists by enrolling subjects with genetic variants in two candidate genes (GIPR and GCGR) in the Old Order Amish.

Role: Principal Investigator

In the News

Link to article by Gina Kolata (The New York Times; July 22, 2016) describing Dr. Taylor's pioneering role in developing metreleptin as a therapy for generalized lipodystrophy.

http://www.nytimes.com/2016/07/26/health/skinny-fat.html?_r=0